Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
79.64
+1.16 (1.48%)
At close: Dec 5, 2025, 4:00 PM EST
79.89
+0.25 (0.31%)
After-hours: Dec 5, 2025, 7:54 PM EST
Revolution Medicines Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
534
Market Cap
15.40B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
RVMD News
- 17 days ago - Revolution Medicines, Inc. (RVMD) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 24 days ago - Revolution Medicines, Inc. (RVMD) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript - Seeking Alpha
- 4 weeks ago - Revolution Medicines, Inc. (RVMD) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress - GlobeNewsWire
- 4 weeks ago - Revolution Medicines to Participate in November 2025 Investor Conferences - GlobeNewsWire
- 5 weeks ago - Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025 - GlobeNewsWire
- 5 weeks ago - Revolution Medicines' RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer - GlobeNewsWire
- 6 weeks ago - Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor - GlobeNewsWire